Patents by Inventor Yongbo Hu

Yongbo Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intelligent glass and intelligent window system
    Patent number: 11951814
    Abstract: The embodiments of the disclosure provide an intelligent glass and an intelligent window system, and relates to the technical field of window display. The intelligent glass of the disclosure includes a touch display assembly and a glass assembly. The touch display assembly is communicatively coupled to the glass assembly, and is configured to send a corresponding dimming instruction to the glass assembly based on a received touch instruction, such that the glass assembly adjusts its light transmittance based on the dimming instruction.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: April 9, 2024
    Assignee: BOE TECHNOLOGY GROUP CO., LTD.
    Inventors: Yongbo Wang, Chen Meng, Zhong Hu, Yutao Tang, Wenjie Zhong, Dahai Hu, Wei Shi
  • Sting modulator compounds, and methods of making and using
    Patent number: 11542293
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: January 3, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stepan Vyskocil, Jeffrey Ciavarri, Courtney Cullis, Dylan Bradley England, Alexandra E. Gould, Paul Greenspan, Yongbo Hu, Steven Langston, Gang Li, Hirotake Mizutani, Masanori Okaniwa
  • ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220411404
    Abstract: The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
    Type: Application
    Filed: May 10, 2022
    Publication date: December 29, 2022
    Inventors: David A. Scott, David Heppner, Thomas Gero, Courtney A. Cullis, Ciric To, Shih-Chung Huang, Yongbo Hu, Steve Stroud, Tyler Beyett, Michael Eck, Nathanael S. Gray
  • ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220378757
    Abstract: The disclosure relates to a compound of Formula (I), which acts as an allosteric inhibitor of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compound; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 1, 2022
    Inventors: Courtney A. Cullis, Krista E. Gipson, Yongbo Hu, Shih-Chung Huang, Nathanael S. Gray, David A. Scott, Thomas Gero, David Heppner, Tyler Beyett, Ciric To, Michael Eck
  • STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING
    Publication number: 20210171565
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 10, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Stepan VYSKOCIL, Jeffrey CIAVARRI, Courtney CULLIS, Dylan Bradley ENGLAND, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Steven LANGSTON, Gang LI, Hirotake MIZUTANI, Masanori OKANIWA
  • STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING
    Publication number: 20210015915
    Abstract: The present disclosure provides novel compounds of Formula (I) below. Compounds of the disclosure act as STING modulators/agonists. The present disclosure further relates to methods of synthesis of compounds of Formula (I) and methods of using of compounds of Formula (I) for the prophylaxis or treatment of cancer and other STING-related diseases. The compounds have the structure represented by Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 21, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jeffrey CIAVARRI, Dylan Bradley ENGLAND, Kenneth M. GIGSTAD, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Shi-Chung HUANG, Steven Paul LANGSTON, Hirotake MIZUTANI, Zhan SHI, Stepan VYSKOCIL, He XU
  • Heteroaryls and uses thereof
    Patent number: 10538533
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: January 21, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • Methods useful in the synthesis of halichondrin B analogs
    Patent number: 10450324
    Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: October 22, 2019
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yongbo Hu, Huiming Zhang, Hiroyuki Chiba, Yuki Komatsu, Bryan M. Lewis
  • Heteroaryls and uses thereof
    Patent number: 10202373
    Abstract: The present invention provides a compound of formula I: wherein R1, X1, X2, R2, R3, R4, R5, n, and m are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: February 12, 2019
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, He Xu, Yingchun Ye
  • METHODS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS
    Publication number: 20190010166
    Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).
    Type: Application
    Filed: July 10, 2018
    Publication date: January 10, 2019
    Inventors: Yongbo HU, Huiming ZHANG, Hiroyuki CHIBA, Yuki KOMATSU, Bryan M. LEWIS
  • Quinoxaline compounds and uses thereof
    Patent number: 10144742
    Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 4, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
  • Methods useful in the synthesis of halichondrin B analogs
    Patent number: 10030032
    Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 24, 2018
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yongbo Hu, Huiming Zhang, Hiroyuki Chiba, Yuki Komatsu, Bryan M. Lewis
  • HETEROARYLS AND USES THEREOF
    Publication number: 20180118762
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: August 1, 2017
    Publication date: May 3, 2018
    Inventors: Indu T. BHARATHAN, Chris BLACKBURN, Jeffrey P. CIAVARRI, Jouhara CHOUITAR, Courtney A. CULLIS, Natalie D'AMORE, Paul E. FLEMING, Kenneth M. GIGSTAD, Krista E. GIPSON, Mario GIRARD, Yongbo HU, Janice LEE, Gang LI, Mansoureh REZAEI, Michael D. SINTCHAK, Francois SOUCY, Stephen G. STROUD, Tricia J. VOS, Tzu-Tshin WONG, He XU, Tianlin XU, Yingchun YE
  • Heteroaryls and uses thereof
    Patent number: 9802960
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: October 31, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • METHODS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS
    Publication number: 20170298078
    Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).
    Type: Application
    Filed: June 30, 2017
    Publication date: October 19, 2017
    Inventors: Yongbo HU, Huiming ZHANG, Hiroyuki CHIBA, Yuki KOMATSU, Bryan M. LEWIS
  • Heteroaryls and uses thereof
    Patent number: 9751854
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 5, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • Methods useful in the synthesis of halichondrin B analogs
    Patent number: 9695188
    Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 4, 2017
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yongbo Hu, Huiming Zhang, Hiroyuki Chiba, Yuki Komatsu, Bryan M. Lewis
  • QUINOXALINE COMPOUNDS AND USES THEREOF
    Publication number: 20170174704
    Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
    Type: Application
    Filed: April 17, 2015
    Publication date: June 22, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
  • HETEROARYLS AND USES THEREOF
    Publication number: 20170073326
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: November 9, 2016
    Publication date: March 16, 2017
    Inventors: Indu T. BHARATHAN, Chris BLACKBURN, Jeffrey P. CIAVARRI, Jouhara CHOUITAR, Courtney A. CULLIS, Natalie D'AMORE, Paul E. FLEMING, Kenneth M. GIGSTAD, Krista E. GIPSON, Mario GIRARD, Yongbo HU, Janice LEE, Gang LI, Mansoureh REZAEI, Michael D. SINTCHAK, Francois SOUCY, Stephen G. STROUD, Tricia J. VOS, Tzu-Tshin WONG, He XU, Tianlin XU, Yingchun YE
  • Intermediates for the preparation of analogs of halichondrin B
    Patent number: RE47797
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 7, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Farid Benayoud, Trevor Lee Calkins, Charles E. Chase, William Christ, Bryan M. Lewis, Matthew Schnaderbeck, Marc Pesant, Brian Austad, Silvio Campagna, Yongbo Hu, Gordon Wilkie, Xiaojie Zhu, Francis G. Fang